SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection
Public ClinicalTrials.gov record NCT01962441. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3B Randomized, Open-Label, Multi-Center Trial Assessing Sofosbuvir + Ribavirin for 16 or 24 Weeks and Sofosbuvir + Pegylated Interferon + Ribavirin for 12 Weeks in Subjects With Genotype 2 or 3 Chronic HCV Infection.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will assess the efficacy, safety, and tolerability of 16 or 24 weeks of sofosbuvir (Sovaldi®; SOF) + ribavirin (RBV), and 12 weeks of SOF+RBV+ pegylated interferon (Peg-IFN) in treatment-naive and treatment-experienced adults with chronic genotype 3 hepatitis C virus (HCV) infection, and treatment-experienced adults with cirrhosis and chronic genotype 2 HCV infection.
Study identification
- NCT ID
- NCT01962441
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 601 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 23, 2013
- Primary completion
- Jan 6, 2015
- Completion
- Jul 6, 2016
- Last update posted
- Jun 19, 2017
2013 – 2016
United States locations
- U.S. sites
- 23
- U.S. states
- 14
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Riverside | California | 92501 | — |
| Not listed | San Diego | California | 92123 | — |
| Not listed | San Francisco | California | 94115 | — |
| Not listed | Aurora | Colorado | 80045 | — |
| Not listed | Englewood | Colorado | 80113 | — |
| Not listed | Miami | Florida | 33136 | — |
| Not listed | Wellington | Florida | 33414 | — |
| Not listed | Marietta | Georgia | 30060 | — |
| Not listed | New Orleans | Louisiana | 70121 | — |
| Not listed | Boston | Massachusetts | 02215 | — |
| Not listed | Novi | Michigan | 48377 | — |
| Not listed | Saint Paul | Minnesota | 55114 | — |
| Not listed | Hillsborough | New Jersey | 08844 | — |
| Not listed | Newark | New Jersey | 07102 | — |
| Not listed | Binghamton | New York | 13903 | — |
| Not listed | New York | New York | 10021 | — |
| Not listed | Germantown | Tennessee | 38138 | — |
| Not listed | Nashville | Tennessee | 37211 | — |
| Not listed | Nashville | Tennessee | 37212-1610 | — |
| Not listed | Arlington | Texas | 76012 | — |
| Not listed | Austin | Texas | 78705 | — |
| Not listed | Norfolk | Virginia | 23502 | — |
| Not listed | Seattle | Washington | 98101 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 55 non-U.S. sites.
Recently updated Hepatitis C trials
Other public records listing Hepatitis C. Sorted by last update posted; newest first. Not a recommendation.
- NCT05181826: Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer Recruiting
- NCT02995252: The HOPE Study: Characterizing Patients With Hepatitis B and C Active, not recruiting
- NCT06409169: DBS TaT in Peer-assisted Telemedicine for Hepatitis C Active, not recruiting
- NCT01644903: Proteogenomic Monitoring and Assessment of Liver Transplant Recipients Recruiting
- NCT00001971: Evaluation of Patients With Liver Disease Recruiting
- NCT07040319: Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01962441, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 19, 2017 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01962441 live on ClinicalTrials.gov.